Preparation of mesoporous silica nanoparticles with controlled pore size, particle diameter, morphology, and structure by two-step process of chlorosilane residue

Xu, Biao; Su, Yonghong; Chen, Liang; Cai, Jixiang; Huang, Bing

doi:10.1016/j.ceramint.2018.08.345

Cited by 14 publications

(9 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To increase the pore size, several studies have used a pore expander. In distinct efforts, a pore size of 5.3 nm was obtained using trimethyl benzene as a pore expander; while using tri-isopropylbenzene, >10 nm pore sizes could be obtained [ 101 , 102 , 103 ]. The functioning of a pore expander is based on a proportional relationship between pore size and the quantity of pore expander added [ 104 ].…”

Section: Promising Aspects Of Mesoporous Silica Nanoparticles As Drug...mentioning

confidence: 99%

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leading to relapse with consequent invasion and metastasis. Treatment with CDs is indeed well-versed but it is badly curtailed with accompanying side effects and inadequacies of site-specific drug delivery. As a result, drug carriers ensuring stealth delivery and sustained drug release with improved pharmacokinetics and biodistribution are urgently needed. Core–shell mesoporous silica nanoparticles (MSNPs) have recently been a cornerstone in this context, attributed to their high surface area, low density, robust functionalization, high drug loading capacity, size–shape-controlled functioning, and homogeneous shell architecture, enabling stealth drug delivery. Recent interest in using MSNPs as drug delivery vehicles has been due to their functionalization and size–shape-driven versatilities. With such insights, this article focuses on the preparation methods and drug delivery mechanisms of MSNPs, before discussing their emerging utility in BC treatment. The information compiled herein could consolidate the database for using inorganic nanoparticles (NPs) as BC drug delivery vehicles in terms of design, application and resolving post-therapy complications.

show abstract

Section: Promising Aspects Of Mesoporous Silica Nanoparticles As Drug...mentioning

confidence: 99%

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

show abstract

“…MSNs with pore size up to 5.3 nm successfully obtained with trimethyl benzene (TMB) as the pore expanded [ 53 , 54 ]. Triisopropylbenzene (TIPB) is another common pore expander being used, and the MSNs obtained exhibit pore size up to ten and several nm [ 55 , 56 ]. Dendritic MSNs with extremely large pore size (up to 39.1 nm) was fabricated with sodium heptafluorobutyrate as a pore expander.…”

Section: Fabrication Of Msnsmentioning

confidence: 99%

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

show abstract

“…Within the MSN family, SBA-15 and MCM-41 are the two types of most commonly used MSNs as a protein delivery system. By altering the synthetic condition, such as pH [25], the ratio of silica precursor to surfactant [26], pore expanding agent incorporation [27,28], and hybrid of a template or solution [29,30], its size, pore diameter, and morphology can be tuned. Furthermore, the facile functionalization of MSN with organic or inorganic moieties, typically carried out by one-pot synthesis (co-condensation) and/or post-synthesis (grafting), makes it easy to realize designed loading and controlled release of specific cargoes.…”

Section: Mesoporous Silica Nanoparticles (Msn) As Carriers For Promentioning

confidence: 99%

Smart Mesoporous Silica Nanoparticles for Protein Delivery

Liu

2019

Nanomaterials

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSN) have attracted a lot of attention during the past decade which is attributable to their versatile and high loading capacity, easy surface functionalization, excellent biocompatibility, and great physicochemical and thermal stability. In this review, we discuss the factors affecting the loading of protein into MSN and general strategies for targeted delivery and controlled release of proteins with MSN. Additionally, we also give an outlook for the remaining challenges in the clinical translation of protein-loaded MSNs.

show abstract

Preparation of mesoporous silica nanoparticles with controlled pore size, particle diameter, morphology, and structure by two-step process of chlorosilane residue

Cited by 14 publications

References 57 publications

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Smart Mesoporous Silica Nanoparticles for Protein Delivery

Contact Info

Product

Resources

About